Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
We report a case of a young man affected by Wolf-Parkinson White syndrome, who was diagnosed as having chronic myeloid leukemia. He started imatinib at standard dose of 400 mg/day and he reached a partial cytogenetic response at 6 months, a sub-optimal response according to European LeukemiaNet crit...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SEEd
2015-10-01
|
| Seri Bilgileri: | Clinical Management Issues |
| Konular: | |
| Online Erişim: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1070 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|